Therapure to manufacture VBI coronavirus vaccines

By The Science Advisory Board staff writers

Therapure Biomanufacturing has signed an agreement with VBI Vaccines for the manufacture of its coronavirus vaccine candidates.

Under the agreement, Therapure will be responsible for the manufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at its facility in Mississauga, Ontario. The company will provide current good manufacturing practice biomanufacturing capabilities to advance the vaccine candidates through clinical studies.

VBI is using its enveloped virus-like particle (eVLP) platform for the development of a preventative pancoronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS), in collaboration with the National Research Council of Canada.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?